

C

a cont

ECNP Research & Scholarship Foundation Annual Report 2023

ECNP Research and Scholarship Foundation Annual Report 2023

1.	About ECNP R&S	3
	Objectives	3
	Board	3
2.	Activities 2023	4
	Scientific and educational meetings	4
	Awards	4
	Other major initiatives	5
3.	Financial Overview	6
	Financial statements	6
4.	Future Outlook	8



The ECNP Research and Scholarship Foundation is a public-interest-serving entity (algemeen nut beogende instelling – ANBI) under Dutch tax law.

1. About ECNP R&S

Objectives

The ECNP Research and Scholarship Foundation (ECNP R&S) is an independent foundation that exists to promote high-quality experimental and clinical research and education in applied and translational neuroscience, with a view to stimulating the development of better treatments for those suffering disorders of the brain.

The object of the Foundation is to create a framework for the organisation of the annual congresses of ECNP. It is a non-profit making body.

Address: Daltonlaan 400, 3584 BK Utrecht, The Netherlands

E-mail: secretariat@ecnp.eu

Website: https://www.ecnp.eu

RSIN: 807967087

Dutch Chamber of Commerce number: 41215196

Dutch TAX number: NL807967087B01

ANBI: The ECNP Research and Scholarship Foundation is a public-interest-serving entity (algemeen nut beogende instelling – ANBI) under Dutch tax law.

Board

Martien Kas President The Netherlands Brenda Penninx Treasurer The Netherlands Suzanne Dickson Secretary Sweden

The members of the board receive no remuneration for their role.

Alexander Schubert Executive Director The Netherlands

2. Activities 2023

To execute its mission to support European applied and translational neuroscience, ECNP R&S performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

In 2023 the following programmes were delivered:

Scientific and educational meetings

• ECNP Workshop for Early Career Scientists in Europe

16-19 March 2023 - Nice, France

The Workshop offers 100 European early career scientists three days of intense interaction with research leaders discussing the latest advances and perspectives in translational neuroscience. Funded by ECNP R&S.

• ECNP New Frontiers Meeting: Psychedelics

19-20 March 2023 – Nice, France

A unique platform for focused, high-level exchange between scientists, industry leaders and regulators at the intersection of research science and new treatment development. The 2023 meeting explored topics in the molecular mechanisms, pharmacology, neuroimaging, psychological variables, and clinical trial challenges of psychedelic medicines, as well as regulatory requirements and patient perspectives. Registration and catering was funded by ECNP R&S.

• ECNP Workshop on Clinical Research Methods

8-10 November 2023 – Barcelona, Spain

The Workshop offers 50 European early career scientists three days of training on research methodology and critical approaches to the scientific literature for early career scientists. Tuition, registration, accommodation and catering was funded by ECNP R&S.

Awards

• ECNP Downloads Prize

Awarded to the most-downloaded research paper in the ECNP journal, *Neuroscience Applied* (NSA) in the preceding two years, the award recognises and encourages impactful original research. Supported by ECNP R&S.

Winner 2023: Eline C.H.M. Haijen et al., 'Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study, *Neuroscience Applied* 1, 2022, 101012.

• ECNP Negative Results Prize in Clinical Neuroscience

Awarded to papers that have made exceptional contributions to CNS treatment science by publishing clinical research with negative findings. Supported by ECNP R&S in co-operation with Cohen Veterans Bioscience.

Winner 2023: Boushra Dalile et al., 'Extruded wheat bran consumption increases serum short-chain fatty acids but does not modulate psychobiological functions in healthy men: a randomized, placebo-controlled trial', Frontiers in Nutrition, 9, 2022.

Other major initiatives

• Neuroscience-based Nomenclature (NbN)

This international collaborative venture, led by ECNP, is working to develop a new nomenclature for psychotropic medications grounded in the latest advances in brain science. Unique in its aims and unprecedented in its scope, in 2023 the initiative's NbN app and NbN-ca app for child and adolescent treatments reached over 180,000 downloads worldwide, with translations in French, Spanish and Chinese, and Portuguese and patient-and-family versions in preparation. Funded by ECNP R&S.

Neuroscience Applied

This fully open-access scientific journal targets the intersection between neuroscience, applications and new treatment horizons, and features original basic, clinical and integrative research with translational relevance for mental health. Focusing especially on neuroscientific approaches to brain disorders, it encompasses mechanisms of disorders, biological, psychological and social treatments, prevention and policies. The journal is fully owned by ECNP R&S.

3. Financial Overview

ECNP R&S's policy is at all times to handle its disposable assets in a responsible and sustainable manner. The principles of this policy are:

- Proactive tax and regulatory compliance
- Strict observance of the requirements of ANBI ('algemeen nut beogende instelling' = public-interest-service entity) status
- Capital preservation
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP R&S invests in securities through an established asset manager using a defensive policy. The goal is to preserve wealth, to ensure the College can continue to perform its public-good activities, not to maximise return.

Financial statements

Balance sheet as at 31 December 2023

(after appropriation of profit/losses)

	31-12-2023		31-12-2022	
	€	€	€	€
ASSETS				
FIXED ASSETS				
Financial fixed assets				
Securities		11,018,368		11,018,368
CURRENT ASSETS				
Accounts receivable				
Debtors Amounts owed by congress foundations Taxes Other accounts receivables	1,484 337,774 1,961 49,054		13,076 309,192 1,377 82,240	
		390,273	02,240	405,885
Bank deposits		2,481,951		2,064,730
		2,872,224	-	2,470,615
	-	13,890,592	=	13,488,983

	31-12-2023		31-12-2022	
	€	€	€	€
EQUITY AND LIABILITIES				
EQUITY AND FUNDS				
Other reserves		13,796,336		13,432,839
CURRENT LIABILITIES				
Trade creditors	14,612		31,521	
Other liabilities	79,644		24,623	
		94,256		56,144
	-	13,890,592	-	13,488,983

Statement of income and expenditure 2023


		Balance 2022
Income	€	€
Proceeds fundraising Journal Neuroscience Applied Neuroscience-based Nomenclature Interest and similar income	1,090,827 20,853 24,805 15,580	696,078 18,000 24,407
Total income	1,152,065	738,485
Expenses		
Administration Meetings Journal Neuroscience Applied Neuroscience-based Nomenclature Other expenses	374,038 308,697 23,000 64,297 16,821	301,137 255,827 29,000 101,637 18,381
Total expenses	786,853	705,982
Balance before financial expense Interest and similar charges	365,212 -1,715	32,503 -6,673
Net result	363,497	25,830
Appropriation of result		
Other reserves	363,497	25,830

4. Future Outlook

The ongoing review of ECNP R&S's purpose and strategy continues, as the College reviews its mission, where the most impactful contribuins can be made, and how relevance and long-term (economic) viability can be assured. Specific issues include:

- How the landscape of European brain science is changing and how ECNP's programmes and activities should adapt to these changes.
- How technology is reshaping the ways in which science is generated, disseminated and consumed, and how ECNP should respond.
- How the organisation's activities can meet the scale of the need they are designed to serve and achieve an impact commensurate with the College's mission.
- How the organisation can fulfil its social obligation to reduce its carbon footprint and contribute to environmental preservation.

Plans are being developed to effect change and renewal in all of these areas and equip the organisation with the structures and systems necessary to meet the next 35 years of its existence. Flagship investments include a full-scale learning management system (LMS) and content library to expand the scale and reach of ECNP's educational activities and make available its significant store of scientific and learning materials.





© 2024 ECNP Research and Scholarship Foundation